Fig. 1From: Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHDDiagram of health states. Patients may enter the model in the mild, moderate, or severe states. Adapted from Sikirika et al. 2012Back to article page